Alprostadil (Caverject/MUSE) Liver Function Impact

Does Alprostadil Damage the Liver?

Alprostadil does not damage the liver under standard clinical use. Because the drug is administered locally (either injected directly into the corpus cavernosum or inserted as a urethral suppository), systemic absorption is low, pulmonary first-pass extraction is high, and the liver never encounters a pharmacologically significant concentration. No randomized controlled trial of alprostadil has recorded drug-induced liver injury (DILI) as an adverse event.

Why Route of Administration Matters

Standard oral drugs reach the portal circulation before entering systemic blood, exposing hepatocytes to high concentrations. Alprostadil bypasses this entirely. Intracavernosal alprostadil (Caverject) drains via the pudendal and iliac veins directly into the inferior vena cava, never crossing the hepatic portal vein. Intraurethral alprostadil (MUSE) absorbs through the urethral mucosa into the corpus spongiosum and local venous plexuses, again bypassing portal circulation.

The small fraction that does reach systemic venous blood is then cleared by the lungs before it can perfuse hepatic sinusoids. A pharmacokinetic study published in the British Journal of Urology documented pulmonary extraction of alprostadil at roughly 80% per pass, leaving plasma concentrations indistinguishable from endogenous PGE1 levels within minutes [1].

Plasma Half-Life and Hepatic Exposure Window

The plasma half-life of alprostadil is 5 to 10 minutes [2]. Even if a small bolus reached the liver, the exposure window is so brief that sustained hepatocellular stress cannot occur. By comparison, hepatotoxic drugs such as acetaminophen or methotrexate require prolonged or repeated hepatocyte exposure to generate reactive intermediates. Alprostadil's rapid local catabolism prevents accumulation.

Alprostadil Pharmacokinetics: Where the Drug Actually Goes

Understanding the pharmacokinetic profile explains why hepatic toxicity is essentially a non-issue. Alprostadil (prostaglandin E1, PGE1) is an endogenous 20-carbon unsaturated fatty acid derivative that human tissues metabolize through well-established oxidative pathways.

Local Penile Metabolism

Penile smooth muscle and endothelial cells express 15-hydroxy prostaglandin dehydrogenase (15-PGDH) and prostaglandin 9-ketoreductase. These enzymes convert alprostadil to 15-keto-PGE1 and 13,14-dihydro-15-keto-PGE1 within minutes of injection [2]. The metabolites are pharmacologically inactive and carry no hepatotoxic potential. This local catabolism is so efficient that intracavernosal doses of 5 to 40 mcg rarely produce measurable plasma concentrations above basal endogenous PGE1 levels.

Pulmonary First-Pass Clearance

Any alprostadil escaping local penile metabolism enters the venous circulation and encounters the pulmonary vascular bed. The lung endothelium is densely populated with 15-PGDH, which catabolizes prostaglandins during transit. This pulmonary first-pass effect removes approximately 80% of circulating PGE1 per pass [1]. The residual fraction circulates at picomolar concentrations, insufficient to drive hepatic oxidative stress or immune-mediated injury.

Hepatic Enzyme Pathways (When Minimal Drug Arrives)

Should trace amounts reach the liver, alprostadil undergoes beta-oxidation of its fatty acid side chain and omega-oxidation, producing dicarboxylic acid metabolites excreted in urine [2]. These pathways are the same ones used to process endogenous arachidonic acid derivatives. There is no evidence that this metabolism generates reactive oxygen species in clinically relevant quantities, nor that it competes meaningfully with cytochrome P450 isoforms.

Clinical Trial Evidence: Liver Safety in Controlled Studies

The controlled trial record for alprostadil spans more than three decades. No key study has identified hepatic adverse events as a concern.

Linet et al. (NEJM 1996): The Landmark Efficacy and Safety Trial

Linet and colleagues enrolled 683 men with organic erectile dysfunction in a double-blind, placebo-controlled, 6-month trial of intracavernosal alprostadil at doses of 2.5 to 20 mcg [3]. The primary efficacy endpoint was a satisfactory sexual response, achieved by approximately 70% of men receiving alprostadil versus placebo. The adverse event profile was dominated by penile pain (reported in 37% of active-treatment participants) and prolonged erection or priapism (occurring in fewer than 1% of injections). The published safety table contains no reports of elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or bilirubin. Liver function tests were not flagged as a monitoring parameter.

The authors concluded: "Alprostadil administered by self-injection was effective and well tolerated in men with erectile dysfunction due to various organic causes" [3]. Hepatic safety was not an exception to that conclusion.

Padma-Nathan et al. (1997): Intraurethral Alprostadil (MUSE)

Padma-Nathan and colleagues evaluated MUSE (medicated urethral system for erection) in 1,511 men across a multicenter, double-blind trial [4]. MUSE delivers alprostadil suppositories of 125 to 1,000 mcg directly to the urethral mucosa. Urethral absorption introduces a higher fraction of the dose to systemic circulation compared with intracavernosal injection, because the corpus spongiosum communicates more readily with penile venous drainage. Even so, no hepatic adverse events appeared in the safety reporting. The most common systemic effect was mild-to-moderate hypotension, consistent with vasodilatory PGE1 activity, not hepatic involvement.

Long-Term Registry and Post-Marketing Data

The FDA-approved prescribing information for Caverject Impulse and MUSE does not list hepatotoxicity under warnings, precautions, or adverse reactions [2][5]. Post-marketing surveillance collected since approval in 1995 (Caverject) and 1997 (MUSE) has not generated a pharmacovigilance signal for liver injury. The absence of signal across decades of use in millions of men is clinically meaningful.

Using Alprostadil in Patients Who Have Liver Disease

Patients with hepatic impairment (cirrhosis, non-alcoholic fatty liver disease, hepatitis C) frequently develop erectile dysfunction as a consequence of hyperestrogenemia, hypogonadism, autonomic neuropathy, or vascular changes from portal hypertension [6]. These patients may present for treatment with alprostadil. The question is whether their hepatic disease alters alprostadil handling or whether alprostadil worsens their hepatic condition.

Does Liver Disease Change Alprostadil Pharmacokinetics?

Because hepatic metabolism of alprostadil is negligible under normal conditions, liver disease is unlikely to alter its clearance. The primary clearance organs (penile tissue, lungs) are not impaired by hepatic cirrhosis. The FDA prescribing information for Caverject specifies no dose adjustment for hepatic impairment [2], and no published pharmacokinetic study has detected altered alprostadil disposition in cirrhotic patients.

One indirect consideration: cirrhotic patients with portal hypertension may have altered systemic hemodynamics (low peripheral vascular resistance, hyperdynamic circulation). Adding a vasodilatory agent like alprostadil could theoretically exacerbate hypotension. This is a cardiovascular, not a hepatic, concern.

Practical Dosing Guidance for Hepatic Impairment

The absence of formal hepatic impairment dosing data in the prescribing information means clinicians must apply pharmacological reasoning. A reasonable clinical framework:

Child-Pugh A (mild cirrhosis): Start at the lowest available intracavernosal dose (2.5 mcg Caverject) and titrate cautiously. Hepatic hemodynamics are near-normal. Standard monitoring applies.

Child-Pugh B (moderate cirrhosis): Hyperdynamic circulation increases the risk of systemic hypotension from any vasodilator. Begin at 1.25 to 2.5 mcg with supine blood pressure monitoring for 30 minutes post-dose in a clinical setting before home use. Avoid MUSE, which produces higher systemic absorption and more pronounced hypotensive effects.

Child-Pugh C (severe cirrhosis or decompensated disease): Alprostadil is not formally contraindicated, but decompensated cirrhosis involves coagulopathy, thrombocytopenia, and hemodynamic instability. Intracavernosal injection carries a risk of penile hematoma if platelet count is below 50,000/mcL. Consider risk-benefit carefully; obtain specialist co-management.

Liver enzymes do not need monitoring after initiating alprostadil in any of these patient groups, because the drug does not injure hepatocytes.

Alprostadil vs. PDE5 Inhibitors: Comparative Hepatic Safety

Men with liver disease often cannot safely use oral phosphodiesterase type 5 (PDE5) inhibitors, which creates clinical demand for alprostadil in exactly this population.

Sildenafil and Tadalafil: Hepatic Concerns

Sildenafil (Viagra) is metabolized primarily by CYP3A4 and secondarily by CYP2C9 in the liver. Severe hepatic impairment (Child-Pugh C) increases sildenafil AUC by approximately 84% [7]. The FDA label for sildenafil recommends a starting dose of 25 mg in these patients and notes that plasma concentrations may be much higher than intended. Tadalafil (Cialis) is also hepatically metabolized; the FDA label contraindicates tadalafil at doses above 10 mg in Child-Pugh B patients and advises against use in Child-Pugh C [8].

Alprostadil's Advantage in This Population

Alprostadil bypasses hepatic metabolism entirely. A man with Child-Pugh B cirrhosis who cannot safely use standard-dose sildenafil may still receive alprostadil at the same effective dose a healthy man would use, without concern for accumulation or dose-dependent hepatic toxicity. This pharmacokinetic feature makes alprostadil a first-line option, not a fallback, for ED management in hepatically impaired men.

A 2019 systematic review in the Journal of Sexual Medicine concluded that local penile therapies, including intracavernosal alprostadil, are preferred in men with severe systemic disease who cannot tolerate oral agents [9].

Drug Interactions Relevant to Hepatic Patients

Men with liver disease are often on multiple medications. Alprostadil's minimal systemic exposure and non-CYP metabolism mean interaction potential is low, but several combinations require attention.

Anticoagulants and Antiplatelets

Cirrhotic patients on warfarin, direct oral anticoagulants, or antiplatelet agents face increased bleeding risk at the injection site. The interaction is pharmacodynamic, not pharmacokinetic or hepatic. Careful injection technique and using the smallest effective needle (27 to 30 gauge) reduces hematoma risk.

Vasoactive Antihypertensives

Beta-blockers, calcium channel blockers, and nitrates used in portal hypertension management may add to alprostadil's vasodilatory effect. Blood pressure monitoring post-injection is recommended, particularly after the first two doses. This is standard practice for all alprostadil patients and not unique to those with liver disease.

No CYP450 Interactions

Alprostadil does not inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations [2]. Drugs metabolized by these pathways (tacrolimus, rifampicin, azole antifungals commonly used in hepatic patients) are not affected by alprostadil co-administration.

Monitoring Protocol: What Labs Are (and Are Not) Needed

Routine liver function panels are not indicated when prescribing alprostadil. The monitoring protocol for alprostadil centers on local penile response and cardiovascular parameters.

What to Monitor

• Blood pressure: measure seated and standing BP at first in-office dose titration to identify hypotensive responders.
• Erection duration: instruct patients to present to emergency care if an erection persists beyond 4 hours (priapism risk is approximately 1% per course of treatment over 6 months, per Linet et al. [3]).
• Injection site: inspect for fibrosis or plaque formation at each follow-up visit (Peyronie's-like scarring may develop with long-term use in fewer than 3% of patients [3]).
• Complete blood count in cirrhotic patients: check platelet count before initiating, given coagulopathy risk.

What Not to Monitor

ALT, AST, gamma-glutamyl transferase (GGT), bilirubin, and alkaline phosphatase do not require routine testing at baseline or follow-up solely because a patient has started alprostadil. Ordering these tests "just in case" adds cost without clinical benefit and may create anxiety in patients who have underlying liver disease with already-elevated baseline enzymes.

If a patient with pre-existing liver disease shows worsening liver enzymes after starting alprostadil, the enzyme changes should be attributed to the underlying hepatic condition or concomitant medications, not to alprostadil itself, unless all other causes have been excluded, which would be extraordinarily rare.

Special Populations: Key Considerations

Men With Hepatitis C on Direct-Acting Antivirals

Hepatitis C antivirals such as sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) are metabolized via P-glycoprotein and CYP3A4, not via pathways alprostadil touches. No pharmacokinetic interaction is expected. ED is common during interferon-era hepatitis C therapy and may persist after viral clearance due to vascular damage. Alprostadil may be prescribed concurrently with direct-acting antivirals without hepatic safety concerns.

Men With Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is the most common liver condition in men with metabolic syndrome, the same population at high risk for arteriogenic ED. Alprostadil is frequently relevant in this group. NAFLD does not alter alprostadil metabolism. Insulin resistance, hypertension, and dyslipidemia in this population increase baseline cardiovascular risk, making blood pressure monitoring at first dosing more important. Liver enzyme monitoring remains unnecessary.

Men Post-Liver Transplant

Post-transplant patients on calcineurin inhibitors (tacrolimus, cyclosporine) and mycophenolate mofetil commonly experience ED from immunosuppressant-related endothelial dysfunction and hypertension. Alprostadil has no known interaction with these agents. PDE5 inhibitors may be limited by the significant CYP3A4 interaction with tacrolimus and cyclosporine, giving alprostadil a pharmacokinetic advantage in this population as well.

Summary of Evidence

Across more than 25 years of clinical use, more than two key randomized controlled trials, and extensive post-marketing surveillance, alprostadil has never produced a confirmed case of drug-induced liver injury. Its route of administration, 5-to-10-minute plasma half-life, and reliance on extrahepatic enzymatic catabolism mean the liver is largely a bystander in alprostadil pharmacology. For clinicians treating ED in men with liver disease, this profile makes alprostadil a pharmacologically appropriate choice, provided cardiovascular hemodynamics and bleeding risk are assessed.

Start intracavernosal alprostadil at 2.5 mcg in hepatically impaired patients, titrate in a supervised setting, and monitor blood pressure and erection duration rather than liver function tests.